<p>HBK Sorce Advisory LLC 在最近向證券交易委員會提交的文件中表示，在第三季度收購了 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - 免費報告) 的新股份。這家機構投資者購買了 76,408 股該生物技術公司的股票，價值約為 2,823,000 美元。截至最近一個季度末，HBK Sorce Advisory LLC 擁有 Arrowhead Pharmaceuticals 約 0.06% 的股份。</p>
<ul>
<li>想要在生物技術領域獲得多元化的上漲潛力？查看 LABU</li>
</ul>
<p>其他大型投資者也買賣了該公司的股票。Resona Asset Management Co. Ltd. 在第二季度將其在 Arrowhead Pharmaceuticals 的持股比例提高了 8.7%。Resona Asset Management Co. Ltd. 現在擁有 11,218 股該生物技術公司的股票，價值為 180,000 美元，此前在上個季度又購買了 900 股。Empowered Funds LLC 在第一季度將其在 Arrowhead Pharmaceuticals 的持股提高了 6.9%。Empowered Funds LLC 現在擁有 15,252 股該生物技術公司的股票，價值為 194,000 美元，此前在上個季度又購買了 979 股。GAMMA Investing LLC 在第三季度將其在 Arrowhead Pharmaceuticals 的持股提高了 64.4%。GAMMA Investing LLC 現在擁有 2,626 股該生物技術公司的股票，價值為 91,000 美元，此前在上個季度又購買了 1,029 股。KLP Kapitalforvaltning AS 在第二季度將其在 Arrowhead Pharmaceuticals 的持股提高了 5.2%。KLP Kapitalforvaltning AS 現在擁有 24,300 股該生物技術公司的股票，價值為 384,000 美元，此前在上個季度又購買了 1,200 股。最後，Mirae Asset Global Investments Co. Ltd. 在第二季度將其在 Arrowhead Pharmaceuticals 的持股提高了 29.5%。Mirae Asset Global Investments Co. Ltd. 現在擁有 5,335 股該生物技術公司的股票，價值為 84,000 美元，此前在上個季度又購買了 1,214 股。62.61% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Arrowhead Pharmaceuticals 價格表現</h2>
<p>ARWR 週三開盤價為 69.83 美元。該公司的流動比率為 4.86，速動比率為 4.86，債務與股本比率為 0.43。該股票的市值為 94.9 億美元，市盈率為-872.77，貝塔值為 1.28。該股票的 50 日移動平均價格為 49.81 美元，200 日移動平均價格為 32.05 美元。Arrowhead Pharmaceuticals, Inc. 的 12 個月低點為 9.57 美元，12 個月高點為 72.36 美元。</p>
<h2>Arrowhead Pharmaceuticals 新聞摘要</h2>
<p>以下是本週影響 Arrowhead Pharmaceuticals 的主要新聞：</p>
<ul>
<li>積極情緒：公司計劃在 1 月份進行的投資者活動可能成為近期催化劑：1 月 6 日的 KOL 網絡研討會將展示肥胖項目 ARO‑INHBE 和 ARO‑ALK7 的中期臨牀數據，以及 1 月 12 日在摩根大通醫療會議上的演講。積極的中期數據或受到好評的 JPM 演講可能會提升市場情緒。Arrowhead Pharmaceuticals 將參與即將於 2026 年 1 月舉行的活動。</li>
<li>中性情緒：今天的交易活動低於該股票的平均交易量，這可能會抑制短期波動；基本面資產負債表指標依然強勁（高流動比率/速動比率）。沒有發佈公司指引或重大交易。</li>
<li>消極情緒：多位內部人士在 12 月底出售了股票——包括首席執行官 Christopher Anzalone 和幾位董事——在 SEC 文件中披露並被媒體報道。內部人士的出售可能會被一些投資者解讀為負面，儘管首席執行官仍持有大量股份（數百萬股），且報告的減持在持股比例上變化不大。有關詳細信息，請參見 SEC 文件和媒體報道。首席執行官 Form 4 董事 Form 4 董事 Form 4 董事 Form 4 媒體：內部人士出售</li>
</ul>
<h2>分析師評級變動</h2>
<p>ARWR 已成為多份分析師報告的主題。美國銀行在 12 月 9 日的報告中將 Arrowhead Pharmaceuticals 的目標價從 62.00 美元上調至 81.00 美元，並給予該股票 “買入” 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Arrowhead Pharmaceuticals 的 “賣出（d-）” 評級。Chardan Capital 在 12 月 1 日的研究報告中重申了 “買入” 評級，並設定了 60.00 美元的目標價。摩根士丹利在 11 月 26 日的研究報告中將 Arrowhead Pharmaceuticals 的目標價從 45.00 美元上調至 48.00 美元，並給予該股票 “持平” 評級。最後，加拿大皇家銀行在 12 月 11 日的研究報告中將 Arrowhead Pharmaceuticals 的目標價從 52.00 美元上調至 80.00 美元，並給予該公司 “跑贏大盤” 評級。兩位股票研究分析師對該股票給予了強烈買入評級，五位給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Arrowhead Pharmaceuticals 目前的共識評級為 “適度買入”，共識目標價為 61.89 美元。</p>
<p><strong>查看我們關於 ARWR 的最新研究報告</strong></p>
<h2>Arrowhead Pharmaceuticals 的內部交易</h2>
<p>在關於箭頭製藥的其他消息中，董事 Adeoye Y. Olukotun 於 12 月 19 日星期五出售了 10,000 股公司的股票。股票以平均價格 67.66 美元出售，總交易額為 676,600.00 美元。交易完成後，該董事直接持有 33,600 股公司股票，價值 2,273,376 美元。這代表其持股比例下降了 22.94%。該交易已在向 SEC 提交的文件中披露，具體信息可通過此鏈接查看。此外，董事 William D. Waddill 於 12 月 19 日星期五出售了 8,367 股箭頭製藥的股票。股票以平均價格 67.65 美元出售，總價值為 566,027.55 美元。交易完成後，該董事持有 56,563 股公司股票，價值約為 3,826,486.95 美元。這代表其持股比例下降了 12.89%。有關此次出售的更多細節可在官方 SEC 披露中找到。在上個季度，內部人士出售了 368,736 股公司股票，價值 23,670,228 美元。公司內部人士持有 4.30% 的公司股票。</p>
<h2>關於箭頭製藥</h2>
<p>(免費報告)</p>
<p>箭頭製藥公司是一家臨牀階段的生物製藥公司，專注於 RNA 干擾（RNAi）治療的發現、開發和商業化。自 2008 年成立以來，箭頭製藥利用其專有的遞送平台——內部稱為先進 RNAi 化合物（ARC）技術——來沉默患有遺傳性疾病的患者體內致病基因。該公司的方法旨在提供持久的、針對性的治療，涵蓋多個治療領域。</p>
<p>該公司的產品管線包括多個處於不同開發階段的候選藥物。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過箭頭製藥</li>
<li>可能每月支付高達 4,290 美元的無聊 AI 投資</li>
<li>特朗普的 “美國房地產交易” 解析</li>
<li>在 1 月 1 日之前投資 1,000 美元於此股票 [不是 NVDA]</li>
<li>特朗普做了什麼？？</li>
<li>崩盤前一個月</li>
</ul>
<p><strong>想看看其他對 ARWR 感興趣的對沖基金持有什麼？</strong> 訪問 HoldingsChannel.com，獲取箭頭製藥公司（NASDAQ:ARWR - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元於箭頭製藥嗎？</h2>
<p>在考慮箭頭製藥之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前...而箭頭製藥並不在名單上。</p>
<p>雖然箭頭製藥目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

箭頭制藥

<p>HBK Sorce Advisory LLC 在第三季度收購了 76,408 股箭頭製藥，價值約為 282 萬美元。這次收購代表了該公司約 0.06% 的股份。其他機構投資者也對箭頭製藥的持倉進行了調整。該股票的表現和分析師評級顯示出混合的情緒，部分分析師持積極展望，同時也注意到內部人士的減持</p>

<p>HBK Sorce Advisory LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor acquired 76,408 shares of the biotechnology company's stock, valued at approximately $2,823,000. HBK Sorce Advisory LLC owned about 0.06% of Arrowhead Pharmaceuticals at the end of the most recent quarter.</p>
<div class="lb-trans"><p>HBK Sorce Advisory LLC 在最近向證券交易委員會提交的文件中表示，在第三季度收購了 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - 免費報告) 的新股份。這家機構投資者購買了 76,408 股該生物技術公司的股票，價值約為 2,823,000 美元。截至最近一個季度末，HBK Sorce Advisory LLC 擁有 Arrowhead Pharmaceuticals 約 0.06% 的股份。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技術領域獲得多元化的上漲潛力？查看 LABU</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. Resona Asset Management Co. Ltd. lifted its position in shares of Arrowhead Pharmaceuticals by 8.7% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company's stock valued at $180,000 after buying an additional 900 shares during the last quarter. Empowered Funds LLC lifted its holdings in Arrowhead Pharmaceuticals by 6.9% during the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock valued at $194,000 after purchasing an additional 979 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Arrowhead Pharmaceuticals by 64.4% during the third quarter. GAMMA Investing LLC now owns 2,626 shares of the biotechnology company's stock valued at $91,000 after purchasing an additional 1,029 shares during the last quarter. KLP Kapitalforvaltning AS increased its stake in shares of Arrowhead Pharmaceuticals by 5.2% in the second quarter. KLP Kapitalforvaltning AS now owns 24,300 shares of the biotechnology company's stock worth $384,000 after purchasing an additional 1,200 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Arrowhead Pharmaceuticals by 29.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock worth $84,000 after purchasing an additional 1,214 shares in the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他大型投資者也買賣了該公司的股票。Resona Asset Management Co. Ltd. 在第二季度將其在 Arrowhead Pharmaceuticals 的持股比例提高了 8.7%。Resona Asset Management Co. Ltd. 現在擁有 11,218 股該生物技術公司的股票，價值為 180,000 美元，此前在上個季度又購買了 900 股。Empowered Funds LLC 在第一季度將其在 Arrowhead Pharmaceuticals 的持股提高了 6.9%。Empowered Funds LLC 現在擁有 15,252 股該生物技術公司的股票，價值為 194,000 美元，此前在上個季度又購買了 979 股。GAMMA Investing LLC 在第三季度將其在 Arrowhead Pharmaceuticals 的持股提高了 64.4%。GAMMA Investing LLC 現在擁有 2,626 股該生物技術公司的股票，價值為 91,000 美元，此前在上個季度又購買了 1,029 股。KLP Kapitalforvaltning AS 在第二季度將其在 Arrowhead Pharmaceuticals 的持股提高了 5.2%。KLP Kapitalforvaltning AS 現在擁有 24,300 股該生物技術公司的股票，價值為 384,000 美元，此前在上個季度又購買了 1,200 股。最後，Mirae Asset Global Investments Co. Ltd. 在第二季度將其在 Arrowhead Pharmaceuticals 的持股提高了 29.5%。Mirae Asset Global Investments Co. Ltd. 現在擁有 5,335 股該生物技術公司的股票，價值為 84,000 美元，此前在上個季度又購買了 1,214 股。62.61% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Arrowhead Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 價格表現</h2>
</div><p>ARWR opened at $69.83 on Wednesday. The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $9.49 billion, a P/E ratio of -872.77 and a beta of 1.28. The stock has a 50-day moving average price of $49.81 and a 200-day moving average price of $32.05. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $72.36.</p>
<div class="lb-trans"><p>ARWR 週三開盤價為 69.83 美元。該公司的流動比率為 4.86，速動比率為 4.86，債務與股本比率為 0.43。該股票的市值為 94.9 億美元，市盈率為-872.77，貝塔值為 1.28。該股票的 50 日移動平均價格為 49.81 美元，200 日移動平均價格為 32.05 美元。Arrowhead Pharmaceuticals, Inc. 的 12 個月低點為 9.57 美元，12 個月高點為 72.36 美元。</p>
</div><h2>Arrowhead Pharmaceuticals News Summary</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 新聞摘要</h2>
</div><p>Here are the key news stories impacting Arrowhead Pharmaceuticals this week:</p>
<div class="lb-trans"><p>以下是本週影響 Arrowhead Pharmaceuticals 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Company-scheduled investor activity in January could be a near-term catalyst: a KOL webinar on Jan 6 that will feature interim clinical data for obesity programs ARO‑INHBE and ARO‑ALK7, plus a presentation at the J.P. Morgan Healthcare Conference on Jan 12. Favorable interim data or a well-received JPM presentation could boost sentiment. Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events</li>
<li>Neutral Sentiment: Trading activity is below the stock’s average volume today, which can mute short-term moves; fundamental balance-sheet metrics remain strong (high current/quick ratios). No corporate guidance or major deals were announced.</li>
<li>Negative Sentiment: Multiple insiders sold shares in late December — including CEO Christopher Anzalone and several directors — disclosed in SEC filings and covered by press. Insider sales can be interpreted negatively by some investors even though the CEO retains a very large position (millions of shares) and reported reductions were small percentage changes in holdings. See SEC filings and press coverage for details. CEO Form 4Director Form 4Director Form 4Director Form 4Press: Insider Selling</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：公司計劃在 1 月份進行的投資者活動可能成為近期催化劑：1 月 6 日的 KOL 網絡研討會將展示肥胖項目 ARO‑INHBE 和 ARO‑ALK7 的中期臨牀數據，以及 1 月 12 日在摩根大通醫療會議上的演講。積極的中期數據或受到好評的 JPM 演講可能會提升市場情緒。Arrowhead Pharmaceuticals 將參與即將於 2026 年 1 月舉行的活動。</li>
<li>中性情緒：今天的交易活動低於該股票的平均交易量，這可能會抑制短期波動；基本面資產負債表指標依然強勁（高流動比率/速動比率）。沒有發佈公司指引或重大交易。</li>
<li>消極情緒：多位內部人士在 12 月底出售了股票——包括首席執行官 Christopher Anzalone 和幾位董事——在 SEC 文件中披露並被媒體報道。內部人士的出售可能會被一些投資者解讀為負面，儘管首席執行官仍持有大量股份（數百萬股），且報告的減持在持股比例上變化不大。有關詳細信息，請參見 SEC 文件和媒體報道。首席執行官 Form 4 董事 Form 4 董事 Form 4 董事 Form 4 媒體：內部人士出售</li>
</ul>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>ARWR has been the subject of several analyst reports. Bank of America raised their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, December 9th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, October 8th. Chardan Capital reiterated a &#34;buy&#34; rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st. Morgan Stanley raised their target price on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Wednesday, November 26th. Finally, Royal Bank Of Canada upped their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $61.89.</p>
<div class="lb-trans"><p>ARWR 已成為多份分析師報告的主題。美國銀行在 12 月 9 日的報告中將 Arrowhead Pharmaceuticals 的目標價從 62.00 美元上調至 81.00 美元，並給予該股票 “買入” 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Arrowhead Pharmaceuticals 的 “賣出（d-）” 評級。Chardan Capital 在 12 月 1 日的研究報告中重申了 “買入” 評級，並設定了 60.00 美元的目標價。摩根士丹利在 11 月 26 日的研究報告中將 Arrowhead Pharmaceuticals 的目標價從 45.00 美元上調至 48.00 美元，並給予該股票 “持平” 評級。最後，加拿大皇家銀行在 12 月 11 日的研究報告中將 Arrowhead Pharmaceuticals 的目標價從 52.00 美元上調至 80.00 美元，並給予該公司 “跑贏大盤” 評級。兩位股票研究分析師對該股票給予了強烈買入評級，五位給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Arrowhead Pharmaceuticals 目前的共識評級為 “適度買入”，共識目標價為 61.89 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on ARWR</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 ARWR 的最新研究報告</strong></p>
</div><h2>Insider Transactions at Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>Arrowhead Pharmaceuticals 的內部交易</h2>
</div><p>In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 10,000 shares of the company's stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $67.66, for a total transaction of $676,600.00. Following the completion of the sale, the director directly owned 33,600 shares in the company, valued at $2,273,376. This represents a 22.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director William D. Waddill sold 8,367 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $67.65, for a total value of $566,027.55. Following the completion of the transaction, the director owned 56,563 shares in the company, valued at approximately $3,826,486.95. This represents a 12.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 368,736 shares of company stock worth $23,670,228. Corporate insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在關於箭頭製藥的其他消息中，董事 Adeoye Y. Olukotun 於 12 月 19 日星期五出售了 10,000 股公司的股票。股票以平均價格 67.66 美元出售，總交易額為 676,600.00 美元。交易完成後，該董事直接持有 33,600 股公司股票，價值 2,273,376 美元。這代表其持股比例下降了 22.94%。該交易已在向 SEC 提交的文件中披露，具體信息可通過此鏈接查看。此外，董事 William D. Waddill 於 12 月 19 日星期五出售了 8,367 股箭頭製藥的股票。股票以平均價格 67.65 美元出售，總價值為 566,027.55 美元。交易完成後，該董事持有 56,563 股公司股票，價值約為 3,826,486.95 美元。這代表其持股比例下降了 12.89%。有關此次出售的更多細節可在官方 SEC 披露中找到。在上個季度，內部人士出售了 368,736 股公司股票，價值 23,670,228 美元。公司內部人士持有 4.30% 的公司股票。</p>
</div><h2>About Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於箭頭製藥</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.</p>
<div class="lb-trans"><p>箭頭製藥公司是一家臨牀階段的生物製藥公司，專注於 RNA 干擾（RNAi）治療的發現、開發和商業化。自 2008 年成立以來，箭頭製藥利用其專有的遞送平台——內部稱為先進 RNAi 化合物（ARC）技術——來沉默患有遺傳性疾病的患者體內致病基因。該公司的方法旨在提供持久的、針對性的治療，涵蓋多個治療領域。</p>
</div><p>The company's pipeline includes multiple candidates in various stages of development.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個處於不同開發階段的候選藥物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Trump Did WHAT??</li>
<li>A month before the crash</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過箭頭製藥</li>
<li>可能每月支付高達 4,290 美元的無聊 AI 投資</li>
<li>特朗普的 “美國房地產交易” 解析</li>
<li>在 1 月 1 日之前投資 1,000 美元於此股票 [不是 NVDA]</li>
<li>特朗普做了什麼？？</li>
<li>崩盤前一個月</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ARWR?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 ARWR 感興趣的對沖基金持有什麼？</strong> 訪問 HoldingsChannel.com，獲取箭頭製藥公司（NASDAQ:ARWR - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJXUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ARWR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元於箭頭製藥嗎？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮箭頭製藥之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前...而箭頭製藥並不在名單上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然箭頭製藥目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HBK Sorce Advisory LLC 收購了箭頭製藥（Arrowhead Pharmaceuticals, Inc.）76,408 股股票